Design, Synthesis and Evaluation of Novel Cyclopropanesulfonamide Derivatives for the Treatment of EGFR<sup>C797S</sup> Mutation in Non-Small Cell Lung Cancer.

Drug Des Devel Ther · 2025 · PMC11874779 · PMID 40034406

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

In addition, the phosphorylated proteins ERK downstream of EGFR also showed a trend of down-regulation, which indicated that the target compounds inhibited the activation of the EGFR signalling pathway, thus significantly attenuating the proliferation ability of the cells.

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.

Design, Synthesis and Evaluation of Novel Cyclopropanesulfonamide Derivatives for the Treatment of EGFR&lt;sup&gt;C797S&lt;/sup&gt; Mutation in Non-Small Cell Lung Cancer.

The sentences

Design, Synthesis and Evaluation of Novel Cyclopropanesulfonamide Derivatives for the Treatment of EGFR<sup>C797S</sup> Mutation in Non-Small Cell Lung Cancer.